Please login to the form below

Ariad Pharma

This page shows the latest Ariad Pharma news and features for those working in and with pharma, biotech and healthcare.

of bolt-on acquisitions and licensing deals, including the $5.2bn takeover of cancer company Ariad Pharma.

Takeda's gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy. Takeda took a chance a few weeks ago when it acquired Ariad with lead pipeline prospect Alunbrig still under regulatory review ... Takeda agreed to buy Ariad earlier this year in a $5.2bn
Ariad files early marketing application for brigatinib

Ariad has filed for approval in the US for brigatinib - its second drug - after positive results in lung cancer were reported at the ASCO conference. ... On Friday, the company announced it had licensed Latin American distribution rights to Pint Pharma
Angelini to market Ariad’s Iclusig in Eastern Europe

Comes after leukaemia drug passes EMA safety review. US pharma company Ariad Pharmaceuticals has licensed its cancer drug Iclusig to Italy-based firm Angelini Pharma to market in 23 Eastern European ... Angelini will handle all sales and marketing
Ariad cuts 160 jobs in US after Iclusig suspension

As such, Ariad's job cuts only affect the US, with European roles unaffected. ... Following the reduction, Ariad will be left with 295 employees covering both regions.
Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots. . Investors continued to bail out of Ariad Pharmaceuticals after it was forced to terminate a pivotal trial of its leukaemia drug Iclusig because ... on the market (albeit with more restrictive

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Ariad appoints new CEO

Paris Panayiotopoulos joins the US biotech from EMD Serono. Paris Panayiotopoulos has moved from EMD Serono to join Ariad as its new president and CEO. ... Panayiotopoulos said: “I am very pleased to be joining ARIAD at this exciting time.
Ariad founder Harvey Berger to retire as CEO and chairman

Effective from December 31 or upon finding of successor. Ariad Pharmaceuticals founder Harvey J. ... Marty Duvall, executive VP and chief commercial officer at Ariad, added: “Harvey enthusiastically embraced the evolution of ARIAD into a global
Ariad appoints new board member

Ariad will look to benefit Denner's experience as it prepares to grow the market share of leukaemia drug Iclusig (ponatinib). ... Ariad also announced that another director is due to join the board, bringing the total number of board members to 10.
Jonathan Dickinson joins Ariad from BMS

Will lead launch of chronic myeloid leukaemia treatment Iclusig. Ariad Pharmaceuticals has appointed Bristol-Myers Squibb's (BMS) Jonathan Dickinson as general manager of its European business. ... He joins at an important time for Ariad in Europe as it

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

How to integrate data to drive sales

Inspired by a recent Agnitio roundtable discussion with Allergan, Ariad Pharmaceuticals, Astellas and Ipsen Pharma. As the number of our digital channels and tools continually expand, there are many opportunities to

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Add my company

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls: ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...